Janssen HME Forum webinar archive

Challenging cases in mantle cell lymphoma

23 February 2021 - 50 Minutes

On behalf of the Scientific Committee you are invited to join us for this LIVE interactive broadcast.

Professor Georg Hess and Dr Ana Marin Niebla will discuss challenging cases in mantle cell lymphoma with particular focus on:

•   Risk stratification
•   1st line therapy selection
•   Salvage treatment options
•   Role of transplantation

During the live broadcast you will have the ...

Faculty

Georg Hess

Ana Marín Niebla

EM-49344

$ON DEMAND webinar: A new chapter in the treatment of patients with relapsed/refractory multiple myeloma$

17 February 2021 - 47 Minutes

Video recording by the congress organisers of the Janssen Symposium from the EHA-EBMT 3rd European CAR T-Cell Meeting that took place on 4 February 2021.

Learning objective:

After participating in this webinar, viewers should be able to:

Discuss recent data updates relating to the use of cellular therapies in the management of patients with multiple myeloma
Evaluate how ...

Faculty

María Victoria Mateos

Adam Cohen

EM-53596

What's new in the ESMO guidelines?

11 February 2021 - 48 Minutes

Learning objective:

After participating in this broadcast you should be able to:

Explain the latest updates to the ESMO guidelines for managing patients with multiple myeloma

Moderator:

Mohamad Mohty (France)

Faculty:

Philippe Moreau (France)

Faculty

Mohamad Mohty

Philippe Moreau

EM-48507

Managing hematological malignancies in the COVID-19 era: 12 months on, what have we learned?

9 February 2021 - 49 Minutes

Join our expert faculty for this series of live, interactive broadcasts, each focussed on a specific topic relevant to hematologists treating patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin’s lymphoma (NHL).

Pre-register for your chance to submit questions to our expert faculty in advance of each broadcast. During each live broadcast you will also be able ...

Faculty

John Gribben

Paolo Ghia

Christian Buske

EM-49343

B-cell malignancies in the spotlight: Interpreting data from ASH 2020

27 January 2021 - 63 Minutes

Learning objective:

After participating in this webinar, viewers should be able to:

Key updates from ASH 2020 on the treatment of mantle cell lymphoma
What’s new in Waldenstrom’s macroglobulinemia?
Updates on B-cell lymphomas: the best of the rest from ASH 2020

Faculty:

Christian Buske (Germany)
Georg Hess (Germany)
Steve Le Gouill (France)
Steven Treon (USA)

Faculty

Christian Buske

Georg Hess

Steven Le Gouill

Steve Treon

EM-49331

Will ASH 2020 change how we manage CLL?

26 January 2021 - 62 Minutes

Learning objective:

After participating in this webinar, viewers should be able to:

Which frontline treatment for your CLL patients?
What does ASH 2020 promise for the future of CLL?

Faculty:

Ulrich Jäger (Austria)
John Gribben (UK)
Paolo Ghia (Italy)
Peter Hillmen (UK)

Faculty

Ulrich Jäger

John Gribben

Paolo Ghia

Peter Hillmen

EM-49329

$The evolution of treatment options for patients with relapsed/refractory multiple myeloma$

21 January 2021 - 63 Minutes

Learning objective:

After participating in this webinar, viewers should be able to:

Updates from ASH 2020 on the management of patients with relapsed / refractory MM

Faculty:

Michel Delforge (Belgium)
Maria-Victoria Mateos (Spain)

Faculty

Michel Delforge

María Victoria Mateos

EM-49327

Key considerations when managing patients with newly diagnosed multiple myeloma and amyloidosis

20 January 2021 - 46 Minutes

Learning objective:

After participating in this webinar, viewers should be able to:

Evaluating the data from ASH 2020 on the management of patients with newly diagnosed MM

Faculty:

Michel Delforge (Belgium)
Maria-Victoria Mateos (Spain)

Faculty

Michel Delforge

María Victoria Mateos

EM-49326

Perspectives on current treatment modalities for older patients with acute myeloid leukemia (AML)

12 January 2021 - 47 Minutes

Learning objective:

After participating in this webinar, viewers should be able to:

Discuss the data from ASH2020 relating to the current management of older or unfit patients with acute myeloid leukemia

Moderator: Charles Craddock (United Kingdom)

Faculty:

Uwe Platzbecker (Germany)
Agnieszka Wierzbowska (Poland)

Faculty

Charles Craddock

Uwe Platzbecker

Agnieszka Wierzbowska

EM-48614

$ASH 2020 data on management of relapsed/refractory MM: what's for my practice?$

11 January 2021 - 49 Minutes

Learning objective:

After participating in this broadcast you should be able to:

Evaluate how data from ASH 2020 relating to the management of patients with relapsed/refractory MM could impact on daily clinical practice

Moderator:

Mohamad Mohty (France)

Faculty:

Philippe Moreau (France)

Faculty

Mohamad Mohty

Philippe Moreau

EM-45078

1
2
3
4